PepGen Inc. (PEPG)
PEPG trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PEPG on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001835597 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $22.0M cash; operating cash flow -$15.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 69,261,282 (2026-11-04); 68,748,224 a year earlier; 23,813,547 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-11-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Diego, California, United States | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $59K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$19.4M | -$13.2M | $22.0M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$17.8M | -$15.8M | $22.8M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$17.8M | -$18.4M | $42.1M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | -$18.3M | -$15.8M | $60.5M | No debt tags | Needs four quarters | 10-K 2026-03-04 |
| Q3 2025 2025-09-30 | Not filed | -$18.0M | -$19.3M | $142.8M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$23.1M | -$23.6M | $35.1M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$30.2M | -$22.9M | $43.6M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | Not filed | -$22.2M | -$19.5M | $49.4M | No debt tags | Needs four quarters | 10-K 2026-03-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-12 |
| Latest annual report | 10-K | 2026-03-04 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 309 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +76.5% |
| 1 month | +74.4% |
| 3 months | +46.3% |
| Year to date | -33.0% |
| 1 year | -10.8% |
| From 52-week high | -39.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IRD | Opus Genetics Inc. | $4.04 | +1.51% | $390.5M |
| RLMD | Relmada Therapeutics Inc. | $3.61 | -14.25% | $385.2M |
| CRMD | CorMedix Inc. | $4.82 | +3.43% | $383.4M |
| PRTA | Prothena Corporation plc | $7.97 | -2.33% | $409.3M |
| CTNM | Contineum Therapeutics Inc. | $9.67 | -1.93% | $379.7M |
| PBYI | Puma Biotechnology Inc | $7.34 | -5.53% | $379.5M |
| AVTX | Avalo Therapeutics Inc. | $7.37 | -5.03% | $426.2M |
| SPRY | ARS Pharmaceuticals Inc. | $3.59 | -7.71% | $360.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier